Patient and Health Care Provider Perspectives on Long Acting Injectable Antipsychotics in Schizophrenia and the Introduction of Olanzapine Long-Acting Injection

Patient and Health Care Provider Perspectives on Long Acting Injectable Antipsychotics in Schizophrenia and the Introduction of Olanzapine Long-Acting Injection

Show other versions (1)

Bibliographic Details
Main Authors:	Heidi J. Wehring, Sheryl Thedford, Maju Koola, Deanna L. Kelly
Format:	Article
Language:	English
Published:	SAGE Publishing 2011-06-01
Series:	Journal of Central Nervous System Disease
Online Access:	http://www.la-press.com/patient-and-health-care-provider-perspectives-on-long-acting-injectabl-a2693

Similar Items

Patient and Health Care Provider Perspectives on Long Acting Injectable Antipsychotics in Schizophrenia and the Introduction of Olanzapine Long-Acting Injection
by: Heidi J. Wehring, et al.
Published: (2011-01-01)

Patient perspectives in the development and use of long-acting antipsychotics in schizophrenia: focus on olanzapine long-acting injection
by: Leslie Citrome
Published: (2009-11-01)

Long-acting injectable antipsychotics: focus on olanzapine pamoate
by: JP Lindenmayer
Published: (2010-05-01)

Long-Acting Injectable Antipsychotics in First-Episode Schizophrenia
by: Eduard Parellada, et al.
Published: (2012-01-01)

The Use of Long-Acting Injectable Antipsychotic Therapy for Schizophrenia
by: Jason Jiang, et al.
Published: (2018-09-01)

Profile of olanzapine long-acting injection for the maintenance treatment of adult patients with schizophrenia
by: Rosaria Di Lorenzo, et al.
Published: (2010-09-01)

Long-Acting Injectable Antipsychotics for First-Episode Schizophrenia: The Pros and Cons
by: Borah Kim, et al.
Published: (2012-01-01)

Switching to olanzapine long-acting injection from either oral olanzapine or any other antipsychotic: comparative post hoc analyses
by: Ciudad A, et al.
Published: (2013-11-01)

An unusual complication of a long-acting injectable antipsychotic: deep venous thrombosis caused by olanzapine pamoate
by: Serhat Tunç, et al.
Published: (2018-04-01)

Long-term functional improvements in the 2-year treatment of schizophrenia outpatients with olanzapine long-acting injection
by: Ascher-Svanum H, et al.
Published: (2014-06-01)

Prescribing practice of long-acting injectable antipsychotics
by: Jisha M Lucca, et al.
Published: (2020-01-01)

Attitudes toward long-acting injectable antipsychotics among patients with schizophrenia in Japan
by: Sugawara N, et al.
Published: (2019-01-01)

Clinical Decision-Making in the Treatment of Schizophrenia: Focus on Long-Acting Injectable Antipsychotics
by: Ludovic Samalin, et al.
Published: (2016-11-01)

The modern perspective for long-acting injectables antipsychotics in the patient-centered care of schizophrenia
by: Pietrini F, et al.
Published: (2019-04-01)

Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, I: analysis of cases
by: Stefaniak Victoria J, et al.
Published: (2010-06-01)

Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, II: investigations of mechanism
by: Stickelmeyer Mary, et al.
Published: (2010-06-01)

Treatment Adherence with Early Prescription of Long-Acting Injectable Antipsychotics in Recent-Onset Schizophrenia
by: Annie Viala, et al.
Published: (2012-01-01)

Second-generation long-acting injectable antipsychotics in schizophrenia: patient functioning and quality of life
by: Montemagni C, et al.
Published: (2016-04-01)

Long-Acting Injectable Antipsychotic Use in Patients with Schizophrenia and Criminal Justice System Encounters
by: Madhav P. Bhatta, et al.
Published: (2021-05-01)

Long-Acting Injectable Antipsychotic Use in Patients with Schizophrenia and Criminal Justice System Encounters
by: Madhav P. Bhatta, et al.
Published: (2021-05-01)

Treatment-completion rates with olanzapine long-acting injection versus risperidone long-acting injection in a 12-month, open-label treatment of schizophrenia: indirect, exploratory comparisons
by: Ascher-Svanum H, et al.
Published: (2012-05-01)

Impact of long-acting injectable antipsychotics on medication adherence and clinical, functional, and economic outcomes of schizophrenia
by: Kaplan G, et al.
Published: (2013-11-01)

Schizophrenia symptoms and functioning in patients receiving long-term treatment with olanzapine long-acting injection formulation: a pooled analysis
by: Peuskens Joseph, et al.
Published: (2012-08-01)

Review of Pharmacokinetics and Pharmacogenetics in Atypical Long-Acting Injectable Antipsychotics
by: Francisco José Toja-Camba, et al.
Published: (2021-06-01)

Attitudes of European physicians towards the use of long-acting injectable antipsychotics
by: Maxine X. Patel, et al.
Published: (2020-03-01)

The evolution of antipsychotic medication: a long-acting injectable formulation of a second-generation antipsychotic
by: Piet Oosthuizen
Published: (2006-06-01)

The use of concurrent long-acting injectable antipsychotic therapy with paliperidone palmitate and aripiprazole monohydrate in a patient with schizophrenia
by: Anderson, M., et al.
Published: (2021)

Role of Long-Acting Injectable Second-Generation Antipsychotics in the Treatment of First-Episode Schizophrenia: A Clinical Perspective
by: Radovan Přikryl, et al.
Published: (2012-01-01)

Aripiprazole Lauroxil, a Novel Injectable Long-Acting Antipsychotic Treatment for Adults with Schizophrenia: A Comprehensive Review
by: Kunal Maini, et al.
Published: (2021-07-01)

Why we should use long-acting injectable antipsychotics more frequently
by: João Paulo Maia-de-Oliveira, et al.
Published: (2013-09-01)

Patients’ experiences of long-acting injectable antipsychotics: a qualitative study
by: Chiu LL, et al.
Published: (2019-07-01)

Exercise and Worsening of Extrapyramidal Symptoms during Treatment with Long-Acting Injectable Antipsychotics
by: David D. Kim, et al.
Published: (2021-07-01)

Use of Aripiprazole Long Acting Injection in Negative Symptoms of Schizophrenia
by: Suneeta James, et al.
Published: (2016-01-01)

Long-Acting Injectable Drugs in the Maintenance Therapy of Patients with Schizophrenia
by: Natalia N. Petrova, et al.
Published: (2020-12-01)

Positive views on antipsychotic long-acting injections: results of a survey of community patients prescribed antipsychotics
by: Shubhra Mace, et al.
Published: (2019-07-01)

Improvement of long-term outcome in schizophrenia: switching to risperidone long-acting injectable
by: Tzanakaki Maria, et al.
Published: (2006-02-01)

Efficacy of olanzapine long-acting injection in patients with acutely exacerbated schizophrenia: an insight from effect size comparison with historical oral data
by: Detke Holland C, et al.
Published: (2012-05-01)

Early response predicts subsequent response to olanzapine long-acting injection in a randomized, double-blind clinical trial of treatment for schizophrenia
by: Stauffer Virginia L, et al.
Published: (2011-09-01)

Initiating long-acting injectable antipsychotics during acute admission for patients with schizophrenia – A 3-year follow-up
by: Chen-Chung Liu, et al.
Published: (2015-06-01)

Effectiveness of Long-Acting Injectable Antipsychotics in Schizophrenia: A Literature Review and Bayesian Meta-Analysis Informing Economic Considerations
by: Orietta Zaniolo, et al.
Published: (2019-02-01)

Cannot write session to /tmp/vufind_sessions/sess_63qqkb645fnmgolmvsrpn9bq0o